ThermoGenesis Holdings, Inc. THMO
At closeNov 2, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 1.58K
- Revenue (ttm)
- 9.61M
- Profit margin
- -153.43%
- EPS (ttm)
- -5.14
- Shares out
- 15.85M
- Forward P/E
- 0.65
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 100
- Avg volume
- 118
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0001
- Beta
- 2.29
- Earnings date
- Dec 23, 2024
2Y -0.0006 (-85.71%)
Key statistics
- Enterprise value
- 5.36M
- PEG ratio
- 0.00
- Price / sales
- 0.21
- Price / book
- 1.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 6.40%
- Free cash flow
- -67.88K
- Total cash
- 1.18M
- Total debt
- 7.57M
- Return on equity
- -801.94%
- Short % of float
- 0.30%
- 50-day average
- 0.4714
- 200-day average
- 0.7407
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate 0.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.02 | — | — | — |
| Oct 3, 2024 | Jun 1, 2024 | 0.02 | — | — | — |
| May 17, 2024 | Mar 1, 2024 | 0.01 | -0.46 | -0.47 | -4,700.00% |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | -2.33 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.21 | -1.44 | -1.23 | -585.71% |
| Aug 10, 2023 | Jun 1, 2023 | 0.01 | -0.91 | -0.92 | -9,200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- thermogenesis.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on THMO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOYALIFE HONG KONG LTD. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 25, 2016 | 6,838,240 |
| BRUCH MICHAEL | Chief Financial Officer | Stock Award(Grant) | Jul 25, 2016 | 30,688 |
| CAUBLE JEFFERY | Officer | Stock Award(Grant) | Jun 29, 2017 | 5,240 |
| ELLNER KIMBERLY KAY | Officer | Stock Award(Grant) | Jul 25, 2016 | 20,818 |
| LIU VIVIAN H | Chief Operating Officer | Stock Award(Grant) | Feb 23, 2017 | 25,000 |
| MOORE CRAIG W | Director | Stock Award(Grant) | Jun 30, 2016 | 7,788 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Raymond James & Associates, Inc. | 2.01% | 50,004 | 64.00K | Jun 29, 2023 |
| Vanguard Group Inc | 1.43% | 35,419 | 45.34K | Jun 29, 2023 |
| Citadel Advisors Llc | 0.54% | 13,421 | 17.18K | Jun 29, 2023 |
| Morgan Stanley | 0.37% | 9,294 | 11.90K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.23% | 5,756 | 7.37K | Jun 29, 2023 |
| Blackrock Inc. | 0.06% | 1,493 | 1.91K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.43% | 35,419 | 45.34K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.06% | 1,538 | 2.00K | May 30, 2023 |
| Fidelity Extended Market Index Fund | 0.03% | 707 | 919 | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 146 | 189 | May 30, 2023 |